Hyperlipidemia

CHICAGO — Two novel agents targeting angiopoietin-like protein 3 demonstrated safety and lipid-lowering capabilities in phase 2 trials, according to findings presented at the American College of Cardiology Scientific Session.

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more than 90 percentage points with a single 400-mg dose compared with placebo, according to results from the ALPACA trial.

WEST PALM BEACH, Fla. — A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients with MS who participated in phase 3 clinical trials of disease-modifying therapies, data show.

The presentation of Cushing’s disease varies by age, with older adults having fewer hallmark features of the condition and more comorbidities, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.

Adults receiving semaglutide for the treatment of obesity were more likely to have antihypertensive or lipid-lowering therapy tapered or discontinued than those receiving placebo, according to data from the STEP trials.

Midlife women with a metabolic dysfunction-associated steatotic liver disease diagnosis were more likely to report severe or very severe hot flashes, though researchers found no direct link between the two conditions, data show.

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, provides an overview of her postgraduate course presentation at the ACG Annual Scientific Meeting.

SAN ANTONIO — In adolescents with obesity, GLP-1 receptor agonists were associated with lower risk for incident hypertension development 5 and 10 years after initiation vs. other anti-obesity medications, a speaker reported.

The FDA has granted breakthrough therapy designation to Arrowhead Pharmaceuticals’ plozasiran, coupled with diet, to decrease triglycerides in patients with familial chylomicronemia syndrome, according to a company release.

Women with vs. without intellectual and developmental disabilities have greater risks for stillbirth and other adverse obstetric, mental health and medical outcomes, according to findings published in JAMA Network Open.